Evaluation of inhibitory drug interactions during drug development: Genetic polymorphisms must be considered
2005; Wiley; Volume: 78; Issue: 1 Linguagem: Inglês
10.1016/j.clpt.2005.04.006
ISSN1532-6535
AutoresL. Andrew Lee, A NAFZIGER, Joseph Bertino,
Tópico(s)Pharmaceutical Practices and Patient Outcomes
ResumoClinical Pharmacology & TherapeuticsVolume 78, Issue 1 p. 1-6 Commentary Evaluation of inhibitory drug interactions during drug development: Genetic polymorphisms must be considered Lois S. Lee PharmD, Lois S. Lee PharmD Clinical Pharmacology Research Center, The Research Institute, Cooperstown, NY Department of Medicine, Bassett Healthcare, Cooperstown, NYSearch for more papers by this authorAnne N. Nafziger MD, MHS, Anne N. Nafziger MD, MHS Clinical Pharmacology Research Center, The Research Institute, Cooperstown, NY Department of Medicine, Bassett Healthcare, Cooperstown, NYSearch for more papers by this authorJoseph S. Bertino Jr PharmD, Corresponding Author Joseph S. Bertino Jr PharmD Clinical Pharmacology Research Center, The Research Institute, Cooperstown, NY Department of Medicine, Bassett Healthcare, Cooperstown, NYScientific Director, Clinical Pharmacology Studies Unit, Ordway Research Institute, 150 New Scotland Ave, Albany, NY 12208 E-mail: [email protected]Search for more papers by this author Lois S. Lee PharmD, Lois S. Lee PharmD Clinical Pharmacology Research Center, The Research Institute, Cooperstown, NY Department of Medicine, Bassett Healthcare, Cooperstown, NYSearch for more papers by this authorAnne N. Nafziger MD, MHS, Anne N. Nafziger MD, MHS Clinical Pharmacology Research Center, The Research Institute, Cooperstown, NY Department of Medicine, Bassett Healthcare, Cooperstown, NYSearch for more papers by this authorJoseph S. Bertino Jr PharmD, Corresponding Author Joseph S. Bertino Jr PharmD Clinical Pharmacology Research Center, The Research Institute, Cooperstown, NY Department of Medicine, Bassett Healthcare, Cooperstown, NYScientific Director, Clinical Pharmacology Studies Unit, Ordway Research Institute, 150 New Scotland Ave, Albany, NY 12208 E-mail: [email protected]Search for more papers by this author First published: 25 July 2005 https://doi.org/10.1016/j.clpt.2005.04.006Citations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Micromedex Healthcare Series. Volume 122. Aripiprazole. Available from: URL: http://www.nt_appsrv/mdx/mdxcgi/display.exe_CTL=d/mdx/mdxcgi/MEGAT.SYS8SET=1C4DBEFB32612A008SYS=18T=1528D=287 Accessed Dec 3, 2004. 2 Abilify (aripiprazole) (2004). Bristol-Myers Squibb: Princeton (NJ). [package insert] 3Meyer, U. A. (1991). Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics 1: 66–67. 4Bachmann, K. A. (2002). Genotyping and phenotyping the cytochrome P-450 enzymes. Am J Ther 9: 309–316. 5Ingelman-Sundberg, M. (2004). Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369: 89–104. 6Ingelman-Sundberg, M. (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25: 193–200. 7Tucker, G. T. (1994). Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 46: 417–424. 8Suzuki, Y., Kawashima, Y., Shioiri, T. and Someya, T. (2004). Effects of concomitant fluvoxamine on the plasma concentration of etizolam in Japanese psychiatric patients: wide interindividual variation in the drug interaction. Ther Drug Monit 26: 638–642. 9Spina, E., Avenoso, A., Facciolà, G., Scordo, M. G., Ancione, M. and Madia, A. (2001). Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 23: 223–227. 10Suri, A. and Bramer, S. L. (1999). Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet 37 (Suppl 2): 53–59. 11Wang, C. Y., Zhang, Z. J., Li, W. B., Zhai, Y. M., Cai, Z. J. and Weng, Y. Z., et al. (2004). The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 44: 785–792. 12Hansten, P. D. (2000). Clinical and pharmacoeconomic significance of metabolic drug interactions. In: R.H. Levy, K.E. Thummel, W.F. Trager, P.D. Hansten, and M. Eichelbaum (Eds). Metabolic drug interactions. Lippincott Williams 88 Wilkins: Philadelphia. 715–721. 13Yu, K. S., Yim, D. S., Cho, J. Y., Park, S. S., Park, J. Y. and Lee, K. H., et al. (2001). Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 69: 266–273. 14Cho, J. Y., Yu, K. S., Jang, I. J., Yang, B. H., Shin, S. G. and Yim, D. S. (2002). Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP 2C19. Br J Clin Pharmacol 53: 393–397. 15Yasui-Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., Inoue, Y. and Kaneko, S., et al. (2004). Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57: 487–494. 16Yasui-Furukori, N., Saito, M., Uno, T., Takahata, T., Sugawara, K. and Tateishi, T. (2004). Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 44: 1223–1229. 17Zanger, U. M. and Eichelbaum, M. (2000). CYP2D6. In: R.H. Levy, K.E. Thummel, W.F. Trager, P.D. Hansten, and M. Eichelbaum (Eds). Metabolic drug interactions. Lippincott Williams 88 Wilkins: Philadelphia. 87–94. 18Rogers, J. F., Nafziger, A. N. and Bertino, J. S., Jr (2002). Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 113: 746–750. 19Zanger, U. M., Raimundo, S. and Eichelbaum, M. (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369: 23–37. 20Ingelman-Sundberg M., Daly A. K., Nebert D. W. Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from: URL: http://www.imm.ki.se/cypalleles/ Accessed Dec 8, 2004. 21Hamelin, B. A., Bouayad, A., Methot, J., Jobin, J., Desgagnes, P. and Poirier, P., et al. (2000). Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67: 466–477. 22Eap, C. B., Lessard, E., Baumann, P., Brawand-Amey, M., Yessine, M. A. and O'Hara, G., et al. (2003). Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13: 39–47. 23Lessard, E., Yessine, M. A., Hamelin, B. A., Gauvin, C., Labbe, L. and O'Hara, G., et al. (2001). Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 21: 175–184. 24Bondolfi, G., Eap, C. B., Bertschy, G., Zullino, D., Vermeulen, A. and Baumann, P. (2002). The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35: 50–56. 25Llerena, A., Berecz, R., de la Rubia, A., Fernandez-Salguero, P. and Dorado, P. (2001). Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 23: 616–620. 26Abdel-Rahman, S. M., Gotschall, R. R., Kauffman, R. E., Leeder, J. S. and Kearns, G. L. (1999). Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 65: 465–472. 27Caraco, Y. (1998). Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit 20: 517–524. 28Touw, D. J. (1997). Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 14: 55–82. 29Brockmoller, J., Kirchheiner, J., Meisel, C. and Roots, I. (2000). Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 1: 125–151. 30 Cytochrome P450 drug interaction table. Available from: URL: http://medicine.iupui.edu/flockhart/table.htm Accessed Dec 8, 2004. 31Spina, E., Scordo, M. G. and D'Arrigo, C. (2003). Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17: 517–538. 32Özdemir, V., Naranjo, C. A., Herrmann, N., Reed, K., Sellers, E. M. and Kalow, W. (1997). Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 62: 334–347. 33Spina, E., Avenoso, A., Scordo, M. G., Ancione, M., Madia, A. and Gatti, G., et al. (2002). Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 22: 419–423. 34Ma, J. D., Nafziger, A. N. and Bertino, J. S., Jr (2004). Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol 44: 447–456. 35Tateishi, T., Kumai, T., Watanabe, M., Nakura, H., Tanaka, M. and Kobayashi, S. (1999). Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 47: 454–457. 36Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. Lancet 356: 1667–1671. 37Furuta, T., Ohashi, K., Kobayashi, K., Iida, I., Yoshida, H. and Shirai, N., et al. (1999). Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 66: 265–274. 38Pinto, A. G., Wang, Y. H., Chalasani, N., Skaar, T., Kolwankar, D. and Gorski, J. C., et al. (2005). Inhibition of human intestinal wall metabolism by macrolide antibiotics: Effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 77: 178–188. Citing Literature Volume78, Issue1July 2005Pages 1-6 ReferencesRelatedInformation
Referência(s)